Cargando…
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
The effect of a single dose of APD on hypercalcaemia has been studied in advanced breast cancer. Twenty-five patients were rehydrated intravenously for 48 h. Twenty-three remained hypercalcaemic and received 5-15 mg APD as a 2 h infusion. Eighteen patients achieved normocalcaemia, 15 after a dose of...
Autores principales: | Coleman, R. E., Rubens, R. D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1987
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001821/ https://www.ncbi.nlm.nih.gov/pubmed/3689664 |
Ejemplares similares
-
Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
por: Coleman, R. E., et al.
Publicado: (1988) -
Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate).
por: O'Rourke, N. P., et al.
Publicado: (1994) -
Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).
por: Ling, P. J., et al.
Publicado: (1995) -
Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?
por: Sydlik, Carmen, et al.
Publicado: (2020) -
Diaquabis(dihydrogen 3-azaniumyl-1-hydroxypropylidene-1,1-diphosphonato-κ(2)
O,O′)cobalt(II)
por: Tsaryk, Natalia V., et al.
Publicado: (2011)